Michael B. Steinberg, MD, MPH; Amy C. Schmelzer, BA; Donna L. Richardson, LCSW, LCADC; Jonathan Foulds, PhD
Grant Support: From the New Jersey Department of Health and Senior Services through the Comprehensive Tobacco Control Program, Robert Wood Johnson Foundation (Drs. Steinberg and Foulds), Cancer Institute of New Jersey (Drs. Steinberg and Foulds), and Pfizer (Dr. Steinberg).
Potential Financial Conflicts of Interest:Consultancies: M.B. Steinberg, J. Foulds (Pfizer, Novartis, GlaxoSmithKline, Celtic Pharma). Honoraria: M.B. Steinberg, J. Foulds (Pfizer Speakers' Bureau). Expert testimony: J. Foulds (provided expert witness testimony against tobacco companies). Grants received: M.B. Steinberg (Pfizer).
Requests for Single Reprints: Michael B. Steinberg, MD, MPH, University of Medicine and Dentistry of New Jersey, School of Public Health, Tobacco Dependence Program, 317 George Street, Room 210, New Brunswick, NJ 08901; e-mail, michael.steinberg@umdnj.edu.
Current Author Addresses: Drs. Steinberg and Foulds, Ms. Schmelzer, and Ms. Richardson: University of Medicine and Dentistry of New Jersey, School of Public Health, 317 George Street, Room 210, New Brunswick, NJ 08901.
Steinberg MB, Schmelzer AC, Richardson DL, et al. The Case for Treating Tobacco Dependence as a Chronic Disease. Ann Intern Med. 2008;148:554–556. doi: https://doi.org/10.7326/0003-4819-148-7-200804010-00012
Download citation file:
© 2019
Published: Ann Intern Med. 2008;148(7):554-556.
DOI: 10.7326/0003-4819-148-7-200804010-00012
Cardiology, Coronary Risk Factors, Smoking, Tobacco, Alcohol, and Other Substance Abuse.
Results provided by: